(SLE)
BEFOVACIMAB(INNC)
IMMUNOGLOBULIN G2-LAMBDA, ANTI-[HOMO SAPIENS TFPI (TISSUE FACTOR PATHWAY INHIBITOR, LIPOPROTEIN-ASSOCIATED COAGULATION INHIBITOR)], MONOCLONAL ANTIBODY; GAMMA2 HEAVY CHAIN HOMO SAPIENS (1-442) [VH (HOMO SAPIENS IGHV3-23*04 (93.9%) -(IGHD) - IGHJ4*01(93.3%)) [8.8.10] (1-117) -HOMO SAPIENS IGHG2*01 (CH1 (118-215), HINGE 1-12 (216-227), CH2 (228-336), CH3 (337-441), CHS K2>DEL (442)) (118- 442)], (131-211')-DISULFIDE WITH LAMBDA LIGHT CHAIN HUMANIZED (1'-212') [V-LAMBDA (HOMO SAPIENS IGLV3-1*01 (86.2%) -IGKJ2*01 (100%)) [6.3.9] (1'- 106') -HOMO SAPIENS IGLC2*01 (100%) (107'-212')]; DIMER (131-219":220-220":223-223":226-226")- TETRAKISDISULFIDE, PRODUCED IN CHINESE HAMSTER OVARY (CHO)-K1SV CELL LINE, GLYCOFORM ALFA. PROPOSED INN LIST 121(WHOM)
BEFOVACIMABUM(INN)